SK150298A3 - Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system - Google Patents

Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system Download PDF

Info

Publication number
SK150298A3
SK150298A3 SK1502-98A SK150298A SK150298A3 SK 150298 A3 SK150298 A3 SK 150298A3 SK 150298 A SK150298 A SK 150298A SK 150298 A3 SK150298 A3 SK 150298A3
Authority
SK
Slovakia
Prior art keywords
antibody
seq
sequence
human
light chain
Prior art date
Application number
SK1502-98A
Other languages
English (en)
Slovak (sk)
Inventor
Clive G Copley
Michael D Edge
Stephen C Emery
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9609405.7A external-priority patent/GB9609405D0/en
Priority claimed from GBGB9703103.3A external-priority patent/GB9703103D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of SK150298A3 publication Critical patent/SK150298A3/sk

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70532B7 molecules, e.g. CD80, CD86
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007Carcino-embryonic Antigens
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
SK1502-98A 1996-05-04 1997-04-29 Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system SK150298A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9609405.7A GB9609405D0 (en) 1996-05-04 1996-05-04 Protein
GBGB9703103.3A GB9703103D0 (en) 1997-02-14 1997-02-14 Protein
PCT/GB1997/001165 WO1997042329A1 (en) 1996-05-04 1997-04-29 Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system

Publications (1)

Publication Number Publication Date
SK150298A3 true SK150298A3 (en) 1999-04-13

Family

ID=26309272

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1502-98A SK150298A3 (en) 1996-05-04 1997-04-29 Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system

Country Status (19)

Country Link
US (2) US6277599B1 (cg-RX-API-DMAC7.html)
EP (1) EP0896626B1 (cg-RX-API-DMAC7.html)
JP (1) JP2000510692A (cg-RX-API-DMAC7.html)
CN (1) CN1217750A (cg-RX-API-DMAC7.html)
AT (1) ATE350478T1 (cg-RX-API-DMAC7.html)
AU (1) AU719513B2 (cg-RX-API-DMAC7.html)
BR (1) BR9708910A (cg-RX-API-DMAC7.html)
CA (1) CA2250579A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ353698A3 (cg-RX-API-DMAC7.html)
DE (1) DE69737188T2 (cg-RX-API-DMAC7.html)
ES (1) ES2279539T3 (cg-RX-API-DMAC7.html)
HU (1) HUP9901562A3 (cg-RX-API-DMAC7.html)
IL (1) IL126772A0 (cg-RX-API-DMAC7.html)
NO (1) NO985120L (cg-RX-API-DMAC7.html)
NZ (1) NZ331978A (cg-RX-API-DMAC7.html)
PL (1) PL329871A1 (cg-RX-API-DMAC7.html)
SK (1) SK150298A3 (cg-RX-API-DMAC7.html)
TR (1) TR199802227T2 (cg-RX-API-DMAC7.html)
WO (1) WO1997042329A1 (cg-RX-API-DMAC7.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU719513B2 (en) * 1996-05-04 2000-05-11 Astrazeneca Ab Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system
AU6000698A (en) * 1997-02-14 1998-09-08 Zeneca Limited Proteins
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
JP2002504372A (ja) * 1998-02-25 2002-02-12 ザ ダウ ケミカル カンパニー 高親和性ヒト型化抗−ceaモノクロ−ナル抗体
EP1131428A2 (en) * 1998-11-19 2001-09-12 Incyte Pharmaceuticals, Inc. Immunoglobulin superfamily proteins
JP2002533072A (ja) * 1998-12-21 2002-10-08 イーライ・リリー・アンド・カンパニー β−リポトロピンおよび他のペプチドの組換え合成
JP2003515323A (ja) * 1999-11-18 2003-05-07 オックスフォード バイオメディカ(ユーケイ)リミテッド 抗 体
GB2371803A (en) * 1999-11-18 2002-08-07 Oxford Biomedica Ltd Antibodies
ES2292587T3 (es) * 2000-04-22 2008-03-16 Pharmedartis Gmbh Agentes apoptoticos.
GB0210783D0 (en) * 2002-05-10 2002-06-19 Polonelli Luciano Anti-microbial polypeptides
KR100604037B1 (ko) * 2002-08-02 2006-07-24 주식회사유한양행 항체 경쇄 카파 발현벡터
US20050008618A1 (en) * 2003-02-27 2005-01-13 Howard Kaufman Composition for delivering an agent to a target cell and uses thereof
WO2004078937A2 (en) * 2003-03-04 2004-09-16 Alexion Pharmaceuticals, Inc. Vectors used to create hybrid constant regions
CA2523142A1 (en) * 2003-04-23 2004-11-04 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
US20110160440A1 (en) * 2003-12-12 2011-06-30 Genencor International, Inc. Cab Molecules
US20050232919A1 (en) 2004-02-12 2005-10-20 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
EP1735350B1 (en) * 2004-04-15 2010-08-25 Genencor International, Inc. Anti-cea scfv - beta-lactamase constructs (cab molecules) in adept
CA2585776A1 (en) 2004-10-29 2006-05-11 University Of Southern California Combination cancer immunotherapy with co-stimulatory molecules
CA2600505C (en) 2005-03-10 2016-05-03 Morphotek, Inc. Anti-mesothelin antibodies
JP2009521206A (ja) 2005-04-22 2009-06-04 モルフォテック、インク. 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体
CA2623429C (en) 2005-09-30 2015-01-13 Medimmune Limited Interleukin-13 antibody composition
US8993295B2 (en) 2006-07-20 2015-03-31 The General Hospital Corporation Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
US8043830B2 (en) * 2008-02-01 2011-10-25 The Regents Of The University Of California Biotin-ligase system for secretion of biotinylated protein
CN101607985B (zh) * 2008-12-24 2013-03-27 中国科学院生物物理研究所 抗人cea的单克隆抗体,包含其的组合物,及其用途
CN101704892B (zh) * 2009-12-09 2014-02-12 中国人民解放军军事医学科学院生物工程研究所 一种抗uPAR人源化抗体及其编码基因与应用
MA34004B1 (fr) * 2010-01-28 2013-02-01 Glaxo Group Ltd Protéines de liaison à cd127
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン(シャンハイ)コーポレイション リミテッド 多重特異性Fab融合タンパク質および使用法
ES3033729T3 (en) 2011-10-28 2025-08-07 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
CN102526707B (zh) * 2012-01-13 2015-04-22 成都博发生物技术有限公司 共刺激因子及融合蛋白的新用途
RU2493166C1 (ru) * 2012-04-09 2013-09-20 Общество с ограниченной ответственностью "Технофарма" Наноантитело, специфически связывающее белок сеа, способ его использования для детекции этого белка
CN102838676A (zh) * 2012-09-26 2012-12-26 李彬 一种癌胚抗原单抗及包含该抗体的芯片以及应用
EP2839860B1 (en) 2012-10-12 2019-05-01 MedImmune Limited Pyrrolobenzodiazepines and conjugates thereof
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドMedImmune Limited ピロロベンゾジアゼピン及びその結合体
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
PT3677591T (pt) 2013-04-29 2023-02-17 Teva Pharmaceuticals Australia Pty Ltd Anticorpos anti-cd38 e fusões a interferão alfa-2b atenuado
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドMedImmune Limited ピロロベンゾジアゼピン及びそのコンジュゲート
PE20170908A1 (es) 2014-10-29 2017-07-12 Teva Pharmaceuticals Australia Pty Ltd VARIANTES DE INTERFERON a2b
AU2017233121B2 (en) 2016-03-15 2023-12-21 Itabmed (Hk) Limited Multispecific Fab fusion proteins and use thereof
JP7241677B2 (ja) 2016-07-19 2023-03-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗cd47併用療法
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
CN106749667B (zh) * 2016-12-04 2020-07-14 深圳市国创纳米抗体技术有限公司 一种抗癌胚抗原的纳米抗体及其应用
KR20210016562A (ko) 2018-05-23 2021-02-16 에이디씨 테라퓨틱스 에스에이 분자 애쥬번트
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
US20210128617A1 (en) * 2019-08-27 2021-05-06 The Trustees Of The University Of Pennsylvania SYNTHETIC CARS TO TREAT IL13R-alpha-2 POSITIVE HUMAN AND CANINE TUMORS
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
CN115850483B (zh) * 2020-10-21 2025-09-19 北京纽安博生物技术有限公司 抗CEACAM6单域抗体、人源化单域抗体及其Fc融合蛋白和应用
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
JP2024541058A (ja) 2021-11-03 2024-11-06 ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ. 抗体の特異的共役

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8809616D0 (en) 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
AU6819494A (en) * 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
AU719513B2 (en) * 1996-05-04 2000-05-11 Astrazeneca Ab Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system

Also Published As

Publication number Publication date
US6903203B2 (en) 2005-06-07
AU719513B2 (en) 2000-05-11
ATE350478T1 (de) 2007-01-15
AU2645597A (en) 1997-11-26
EP0896626B1 (en) 2007-01-03
HUP9901562A2 (hu) 1999-08-30
WO1997042329A1 (en) 1997-11-13
NO985120L (no) 1998-12-29
NZ331978A (en) 2000-05-26
TR199802227T2 (xx) 2000-07-21
CA2250579A1 (en) 1997-11-13
ES2279539T3 (es) 2007-08-16
DE69737188T2 (de) 2007-10-11
CN1217750A (zh) 1999-05-26
US6277599B1 (en) 2001-08-21
CZ353698A3 (cs) 1999-02-17
NO985120D0 (no) 1998-11-03
US20020142359A1 (en) 2002-10-03
EP0896626A1 (en) 1999-02-17
HUP9901562A3 (en) 2000-06-28
BR9708910A (pt) 1999-08-03
IL126772A0 (en) 1999-08-17
PL329871A1 (en) 1999-04-12
DE69737188D1 (de) 2007-02-15
JP2000510692A (ja) 2000-08-22

Similar Documents

Publication Publication Date Title
AU719513B2 (en) Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system
AU709503B2 (en) Delivery system using mAb 3E10 and mutants and/or functional fragments thereof
CA2019559C (en) Bispecific and oligospecific mono- and oligovalent receptors, the preparation and use thereof
JP4773097B2 (ja) ヒトインスリン受容体を介する医薬品の送達
JP5719596B2 (ja) 抗体及びその誘導体
EP0731838B1 (en) Binding structures directed against the ca55.1 antigen
US5830478A (en) Method for delivering functional domains of diphtheria toxin to a cellular target
JP3805365B2 (ja) 化合物
AU2004245038A1 (en) De-immunized anti-CD3 antibody
Hoogenboom et al. Cloning and expression of a chimeric antibody directed against the human transferrin receptor.
JP5749009B2 (ja) EphB4に結合するヒト化抗体を利用する癌治療剤
Scallon et al. A review of antibody therapeutics and antibody-related technologies for oncology
KR20000010771A (ko) Cea에 대한 모노클로널 항체, 이 항체를 함유하는 접합체 및adept계에서의 치료적 용도
JPH03254691A (ja) 薬剤耐性癌に対するキメラ抗体およびその製造